Abcam, ab76103, Anti-FYB antibody [EP2546Y]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal FYB antibody. Suitable for IHC-P, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EP2546Y,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:Flow Cyt (Intra), WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please
contact us
for more information.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.05% Sodium azideConstituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein 'FYB' also known as Fyn-binding protein or ADAP (Adhesion and Degranulation-promoting Adapter Protein) is a cytosolic adaptor protein with a molecular mass of approximately 85 kDa. This protein is important for intracellular signaling pathways as it acts as a link between various surface receptors and downstream signaling molecules. FYB is prominently expressed in hematopoietic cells with its presence noted in T-cells where it facilitates effective immune responses. This makes anti-FYB antibodies valuable tools for studying T-cell signaling and immune regulation.
Biological function summary
The Fyn-binding protein plays significant roles in modulating immune responses by interacting with the cytoskeleton and various signaling components. FYB does not normally function alone but exists as part of the LAT (Linker for Activation of T-cells) signalosome complex a multi-protein structure essential for T-cell receptor (TCR) signaling. It influences cytoskeletal rearrangement cell adhesion and migration impacting the immune cell's ability to reach sites of inflammation or infection. Its interaction with integrins further enhances these cellular processes.
Pathways
FYB is integral to T-cell receptor signaling and integrin-mediated signal transduction pathways. In TCR signaling FYB works alongside core proteins such as SLP-76 and Vav1 to propagate activation signals necessary for T-cell activation and proliferation. Within integrin signaling FYB collaborates with Talin and Kindlin to regulate cell adhesion and motility fundamental for immune surveillance and response tasks. The tight regulation of these pathways ensures that immune cells can properly adapt to various immune challenges.
Irregular FYB function associates with defective immune responses and autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis. These conditions arise from aberrant activation or suppression of T-cell signaling where FYB as part of the LAT signalosome indirectly contributes to the pathophysiology. Furthermore FYB interactions with proteins like SLP-76 and Vav1 highlight its potential role in these diseases making it a target for research into therapeutic interventions for T-cell mediated disorders.